Wednesday, January 30, 2013

Astellas to present Overall Survival data on Tivozanib in RCC at ASCO GU Cancer conference 2013

At the upcoming American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 14-16 in Orlando, Florida., Astellas and Aveo will present new clinical data on Tivozanib.
 
 The important presentations at ASCO GU on tivozanib include 
  1. (Abstract #350) Title: Overall Survival Results from a Phase 3 Study of Tivozanib Hydrochloride vs Sorafenib in Patients with Renal Cell Carcinoma
  2. (Abstract#354) Title: Subgroup Analyses of a Phase 3 Trial Comparing Tivozanib Hydrochloride vs Sorafenib as Initial Targeted Therapy for Patients with Metastatic Renal Cell Carcinoma (mRCC)
  3. Abstract #364) Title: Efficacy and Safety Data from Patients with Advanced Renal Cell Cancer Treated with Tivozanib Hydrochloride After Progression on Sorafenib

Enter your email address:


Delivered by FeedBurner